Injection Pen Market Size To Attain US$ 38.27 Bn By 2032

The global injection pen market reached US$ 36 billion in 2022 and is expected to hit over US$ 69.18 billion by 2032 with a CAGR of 6.80% from 2023 to 2032.

The global injection pen market is significantly driven by several factors such as rising prevalence of various chronic diseases, technological advancements in the drug delivery devices, development of innovative drugs, and rising awareness regarding the availability of innovative drugs and drug delivery devices among the population. The regulatory framework of the government regarding the approvals and reimbursement policies is playing a crucial role in the growth of the market. Moreover, the rising number of diabetic population and growing demand for the convenient and easy to use drug delivery solutions at homecare setting is fueling the demand for the injection pen market across the globe.

Get the Report Sample Copy@ https://www.precedenceresearch.com/sample/1497

Report Highlights

Based on the product type, the disposable segment dominated the market in 2020. The more safety associated with the disposable needles and prevention of blood-borne diseases is the major factors that have driven the demand for the disposable injection pens across the globe.
Based on the therapy, the diabetes segment dominated the injection pen market in 2020. The increased demand for the injection pens among the diabetic population for the regular maintenance of blood glucose levels has fostered the growth. The rising prevalence of diabetes is expected to further boost the growth of this segment. According to the International diabetes federation, the global diabetic population is estimated to reach at 783 million by 2045.
Based on the end user, the homecare segment was the leading the market in 2020. The convenience and easy-to-use feature of the injection pens has enabled the patients to self-inject drugs without any medical assistance at home. This saves the cost for the patients.

Regional Snapshot

North America dominated the global injection pen market. The increased prevalence of non-communicable diseases among the US population is a significant driver of the market. Around 60% of the US population is suffering from one or more chronic diseases. The increased healthcare expenditure and easy availability of the injection pen has fostered the demand for the injection pen across North America. Moreover, the presence of geriatric population, who are more susceptible to various chronic diseases are resulting in the bolstering demand for the injection pens. The increased adoption rate of the technologically advanced healthcare devices in the region coupled with the active participation of the government authorities in certifying the new drugs and drug delivery devices have contributed in the market growth.

Asia Pacific is estimated to be the most opportunistic market during the forecast period. This can be attributed to the rising burden of chronic diseases among the population. According to the International Diabetes Federation, 3 in 4 diabetes affected people live in low and middle income countries. Moreover, according to the United Nations, 80% of the global geriatric population will be living in the low and middle income countries by 2050. The rising disposable income, growing healthcare expenditure, rising awareness regarding the innovative drug delivery devices, and increasing investments in the development of advanced healthcare infrastructure are the major driving factors of the Asia Pacific injection pen market.

Table of Contents

Scope of the Injection Pen Market

Report Coverage	Details
Market Size in 2023	USD 38.27 Billion
Growth Rate from 2023 to 2032	6.7%
Largest Market	North America
Fastest Growing Market	Asia Pacific
Base Year	2022
Forecast Period	2023 to 2032
Segments Covered	Product, Therapy, End User, Region

Injection Pen Market Dynamics

Driver

Rapidly growing prevalence of chronic diseases

According to the International Agency for Research on Cancer, in 2020, around 19.3 million new cancer cases and 10 million cancer deaths were reported across the globe. This number is expected to rise by 47% from 2020 to 2040. According to the International Diabetes Federation, currently around 537 million people are living with diabetes and this number is expected to reach at 783 million by 2045. Moreover, cardiovascular diseases accounts for 17.9 million of the global deaths and it is the leading cause of death across the globe. Therefore, the growing incidences of chronic diseases is expected to augment the demand for the injection pens across the globe.

Restraints

Availability of alternative drug delivery solutions

The growing number of needle stick injuries is compelling the consumers to opt for needle free drug delivery devices. Moreover, the rising preferences for the insulin pumps over insulin pens due to the growing needle stick anxiety may decrease the demand for the injection pens. This is a major factors that may hinder the growth of the global injection pen market during the forecast period.

Opportunity

Growing demand for the biosimilars

The development of various biosimilar drugs for the treatment of diseases such as diabetes, cancer, CVD, and autoimmune diseases is gaining rapid traction. The biosimilar drugs are expected to drive the growth of the injection pen market in the forthcoming years as the biosimilar drugs is expected to provide new growth aspects to the market players. Moreover, the regulatory authorities like EMA and FDA are actively participating in the clinical trials, product development, and approvals.

Challenge

Improper use may give rise to needle stick injuries

The lack of proper education and proper use of the injection pens may result in the overdose of the drugs and needle stick injuries to the patients. Moreover, there is a risk of getting affected by blood-borne diseases due to the injection pens. This poses a major threat to the injection pen market, as the aforementioned factors may result in the decline in the demand for the injection pens.

Key Market Developments

In April 2020, Sanofi acquired the US FDA approval for its new prefilled pen named Dupixent that serves the asthma, chronic rhinosinusitis, and atopic dermatitis patients at homecare.
In June 2019, Sanofi acquired the EMA approval for its ToujeoSoloStar Pens in Europe.
In October 2017, Eli Lilly launched Humalog Junior KwikPen for the U.S. diabetic patients.

Some of the prominent players in the global injection pen market include:

Eli Lilly
Novo Nordisk
Sanofi
Merck
AstraZeneca
Ypsomed
F.Hoffman-La Roche
Becton Dickinson and Company
Novartis
Pfizer
Haselmeier
Owen Mumford
WOCKHARDT
Companion Medical

Segments Covered in the Report

By Product Type

Reusable
Disposable

By Therapy

Diabetes
Cancer
Osteoporosis
Autoimmune Diseases
Growth Hormone Therapy
Multiple Sclerosis
Fertility
Cardiovascular Diseases
Others

By End User

Hospitals & Diagnostic Centers
Homecare

By Geography

North America
- U.S.
- Canada
- Mexico
Europe
- U.K.
- Germany
- France
Asia Pacific
- China
- India
- Japan
- South Korea
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of Middle East & Africa